Who are Immunitas Therapeutics's investors?

Immunitas Therapeutics's investors include DC Investment Partners, Longwood Fund, Medical Excellence Capital, Novartis Venture Fund, Ono Venture Investment, Inc., Solasta Ventures, Agent Capital, Leaps by Bayer and 1 more.

How much funding has Immunitas Therapeutics raised?

Immunitas Therapeutics has disclosed $29.1M raised across 1 round.

Where is Immunitas Therapeutics headquartered?

Immunitas Therapeutics is headquartered in Waltham, US.

Immunitas Therapeutics

Waltham, US · Founded 2019 · Delaware corporation · 18 employees on LinkedIn · 9 known investors

Immunitas discovers and develops therapeutic antibodies for cancer and autoimmune diseases, with its lead program targeting CD161 for solid tumors and hematological malignancies. The company is building on research from academic institutions including Dana Farber Cancer Institute and MIT.

Biotech Digital Health Medical Devices

Founders & leadership

Amanda WagnerNamed on SEC filing

Dan MatloffNamed on SEC filing

Jiaping GuNamed on SEC filing

Jeffrey GoldbergNamed on SEC filing

Board

Laura Brass inBoard directorManaging Director at Novartis Venture Fund

Kai WucherpfennigBoard directorStrategic Advisory Board at Longwood Fund

Juergen EckhardtBoard director

Christoph WestphalBoard directorCo-Founder & General Partner at Longwood Fund

Lucio Iannone inBoard Member2019–2025Vice President at Leaps by Bayer

Investors · 9

DC Investment PartnersMcLean · $10M

Longwood FundBostonvia Christoph Westphal · board

Medical Excellence CapitalNew York

Novartis Venture FundBasel · $5M – $25M

Ono Venture Investment, Inc.South San Francisco

Solasta VenturesBoston

Agent Capitalreported · 2 sourcesWaltham

Leaps by BayerreportedLeverkusen

M Venturesreported · 2 sourcesLos Angeles · $10.8M

Reported raises · per SEC filings

Form D private placements

$29.1M disclosed across 1 round · 2021

▶$29.1MraisedAug 2021 · 21 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Laura BrassDirector
Amanda WagnerExecutive Officer
Kai WucherpfennigDirector
Dan MatloffExecutive Officer
Jiaping GuDirector
Jeffrey GoldbergExecutive Officer, Director
Juergen EckhardtDirector
Christoph WestphalDirector
Lucio IannoneDirector

Offering amount: $57.7M
Amount sold: $29.1M
First sale: Aug 2021
Incorporated: Corporation, Delaware, 2019
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 4

by search overlap

Bioworld25 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.

Immunomic Therapeutics21 shared keywordsImmunomic Therapeutics develops nucleic acid immunotherapy platforms, particularly self-amplifying RNA and plasmid DNA vaccines, for cancer treatment, allergies, and animal health applications. The company's UNITE® platform leverages lysosomal targeting technology to generate immune responses against CMV, HPV, and other tumor-associated antigens across multiple cancer types and allergic conditions.

Inimmune19 shared keywordsInimmune is a clinical-stage biotech company that discovers and develops immunotherapies based on innate immune modulation, including Toll-like receptor agonists, to treat inflammatory conditions such as allergy, cancer, and autoimmune disease. Its lead program, INI-2004, is an intranasal TLR4 agonist in Phase 2 trials for allergic rhinitis, alongside INI-4001, a TLR7/8 agonist in Phase 1 oncology trials, plus pre-clinical vaccine adjuvant work.

Solu19 shared keywordsSolu Therapeutics is a clinical-stage biotech developing a class of antibody therapeutics that link bifunctional small molecules to proprietary effector antibodies (its CyTAC and TicTAC platforms) to reach cell surface targets like GPCRs and ion channels. Its pipeline targets oncology, immunology and inflammation, and pain, with a lead program in Phase 1 trials for chronic myelomonocytic leukemia.

Companies competing with Immunitas Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.

In the news

Immunitas Therapeutics Presents Data for Novel Anti CLEC2D-TLR9 Conjugate Program at the Society for Immunotherapy of Cancer 2023 Annual Meetingprnewswire.com · Oct 2023

Immunitas Therapeutics Completes $58 Million Series B Financing to Advance Pipeline into the Clinic and Expand Single Cell Analysis Drug Development Platform for Immuno-Oncology and Other Diseasesprnewswire.com · Aug 2021

Immunitas Therapeutics Launches with $39 Million to Advance Lead Programs to Human Efficacy Studies Based on a Unique Immunology-Focused Drug Development Platform | AP Newsapnews.com · Nov 2019

Immunitas Therapeutics Raises $39M in Series A Funding - FinSMEsfinsmes.com · Nov 2019

Frequently asked questions

What does Immunitas Therapeutics do?: Immunitas discovers and develops therapeutic antibodies for cancer and autoimmune diseases, with its lead program targeting CD161 for solid tumors and hematological malignancies. The company is building on research from academic institutions including Dana Farber Cancer Institute and MIT.
Who are Immunitas Therapeutics's investors?: Immunitas Therapeutics's investors include DC Investment Partners, Longwood Fund, Medical Excellence Capital, Novartis Venture Fund, Ono Venture Investment, Inc., Solasta Ventures, Agent Capital, Leaps by Bayer and 1 more.
How much funding has Immunitas Therapeutics raised?: Immunitas Therapeutics has disclosed $29.1M raised across 1 round.
Where is Immunitas Therapeutics headquartered?: Immunitas Therapeutics is headquartered in Waltham, US.